2021 Revenues ($USD) : $4,697,305,171
2021 Revenues (foreign currencies) : JP¥515,952,000,000
2021 R&D spend : $1,207,957,028.40
2021 Number of Employees : 3067
Fiscal Year End : 3/31/2021
Leader : CEO Hiroshi Nomura

The Osaka, Japan–based company traces its origin to the 2005 merger of Sumitomo Pharmaceuticals and Dainippon Pharmaceuticals. The company has steadily expanded since that merger, acquiring the U.S. firm Sepracor Inc. (now Sunovion) in 2009 and ​​the oncology-focused biotech Boston Biomedical in 2012. The firm entered the field of regenerative medicine and cell therapy a year later. The company currently focuses on psychiatry and neurology, oncology and regenerative medicine/cell therapy. —BB